Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Fecal Microbiota Transplantation by Oral Capsules in Patients With Liver Cirrhosis
NCT06368895Phase 1Completed
- Sponsor
- Policlinico Gemelli
- Start
- Apr 2021
- Primary completion
- Jun 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Fecal Microbiota Transplantation Capsule in hepatic encephalopathy (HE) (3 arms), sponsored by Policlinico Gemelli. Primary endpoints: Safety of fecal microbiota transplantation at 12 months and Efficacy of fecal microbiota transplantation at 12 months. Started Apr 2021; status: completed.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT06368895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06368895.